Germany - quo vadis?

Germany - quo vadis?

Up next

Thinking fast, building slow: The energy cost of the US AI boom

The number of the week is $1.4 billion — that's how much extra US residential households are paying on their electricity bills per year as a direct result of data-center demand. Against this backdrop, preparing energy infrastructure for AI and addressing community concerns is as ...  Show more

Global Insolvency Outlook: Brace for Middle East spillovers

The direct toll of the Middle East crisis is an additional 7000 insolvencies in 2026, according to our latest Global Insolvency Report. This week our AI Assistants Aria and Bob explain which regions are particularly at risk, and what could go wrong. This content was generated by ...  Show more

Recommended Episodes

Money Talks: Why weight-loss drugs will reshape the world
Money Talks from The Economist

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs th ...

  Show more

More Big Tech Results… And Dissecting The Latest Pharma Moves 10/30/25
CNBC's "Fast Money"

Apple & Amazon the latest big tech names to report results. The headlines from the company conference calls, and what top tech analyst Gene Munster sees in store for the group. Plus Eli Lilly jumping as its obesity drug sales soar. How the company is moving the needle in the w ...

  Show more

FDA ends GLP-1 compounding for semaglutide, tirzepatide
Healthcare Strategies

FDA’s removal of GLP-1 drugs from the shortage list ends supplemental compounding, shifting patient access back to branded semaglutide and tirzepatide. Featuring: Sara Heath, executive editor, Xtelligent Healthcare Alivia Kaylor, senior editor of Pharma Life Sciences, Xtelligent ...  Show more

The FDA Boss on the Agency’s MAHA Makeover
The Journal.

Dr. Marty Makary has criticized the Food and Drug Administration for being "captured" by Big Food and Big Pharma. Now, the surgeon and former professor is in charge. In an interview with host Jessica Mendoza, the new FDA head talks about food dyes, AI, vaccines and the big change ...  Show more